Chronic Kidney Disease and HypertensionPhase 3BaxDuo-PacificNCT06742723

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

A Phase 3 study testing Baxdrostat/dapagliflozin in people with Chronic Kidney Disease and Hypertension, run by AstraZeneca at 771 sites in 42 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Chronic Kidney Disease and Hypertension
What is being tested?: Baxdrostat/dapagliflozin
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 5,000 participants
Where: 771 sitesin 42 countries
Study dates: 3 Mar 2025to 18 Dec 2029
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent.
Participants with (a) or (b):
eGFR 30-59 mL/min/1.73 m² (local or central laboratory value) AND:
UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory value only), or
UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or
UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only).

Show all 15Show fewer

eGFR 60-75 mL/min/1.73 m² (local or central laboratory value) AND:
UACR ≥ 500 mg/g (56.5 mg/mmol) ) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or
UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only)
[obsolete]
Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit.
Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit.
Participants with:
Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2 (local or central laboratory values)
Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR < 45 mL/min/1.73 m2 (local or central laboratory values)

Who cannot join

Systolic blood pressure > 180 mmHg, or diastolic BP > 110 mmHg at screening.
Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening.
Serum sodium < 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit).
4. Participants with T1DM will be excluded, except:
For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion.
For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion.

Show all 14Show fewer

5 Uncontrolled T2DM with HbA1c > 10.5% (> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit).
6 New York Heart Association functional HF class IV at screening.
7 Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation.
8 Documented history of adrenal insufficiency.
9 Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit.
10 Any acute kidney injury within 3 months prior to the Screening Visit.
11 History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant).
12 Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1).

Trial locations and contacts

771 sites in 42 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

771 sites in 42 countries

United States135 sites, 112 recruiting

Research Site
Albany, New York, 12205
Recruiting
Research Site
Ann Arbor, Michigan, 48109
Recruiting
Research Site
Arlington, Texas, 76015
Recruiting
Research Site
Arlington, Virginia, 22205
Recruiting
Research Site
Arvada, Colorado, 80002
Recruiting
Research Site
Atlanta, Georgia, 30328
Recruiting
Research Site
Augusta, Georgia, 30904
Withdrawn
Research Site
Austell, Georgia, 30106
Recruiting
Research Site
Austin, Texas, 78726
Recruiting
Research Site
Austin, Texas, 78735
Recruiting
Research Site
Austin, Texas, 78751
Suspended
Research Site
Bethesda, Maryland, 20889
Recruiting
Research Site
Beverly Hills, California, 90211
Recruiting
Research Site
Boca Raton, Florida, 33487
Recruiting
Research Site
Boston, Massachusetts, 02114
Withdrawn
Research Site
Boston, Massachusetts, 02115
Recruiting
Research Site
Boynton Beach, Florida, 33435
Recruiting
Research Site
Braintree, Massachusetts, 02184
Recruiting
Research Site
Bridgeville, Pennsylvania, 15017
Recruiting
Research Site
Brunswick, Georgia, 31520
Recruiting
Research Site
Buffalo, New York, 14203
Recruiting
Research Site
Burlington, Vermont, 05401
Recruiting
Research Site
Butler, Pennsylvania, 16001
Recruiting
Research Site
Canoga Park, California, 91303
Withdrawn
Research Site
Canton, Ohio, 44718
Recruiting
Research Site
Champaign, Illinois, 61822
Recruiting
Research Site
Charleston, South Carolina, 29414
Recruiting
Research Site
Chattanooga, Tennessee, 37421
Recruiting
Research Site
Cincinnati, Ohio, 45212
Recruiting
Research Site
Cincinnati, Ohio, 45219
Recruiting
Research Site
Columbia, South Carolina, 29203
Recruiting
Research Site
Columbus, Ohio, 43210
Recruiting
Research Site
Columbus, Ohio, 43213
Recruiting
Research Site
Columbus, Ohio, 43215
Recruiting
Research Site
Concord, California, 94520
Recruiting
Research Site
Conyers, Georgia, 30094
Recruiting
Research Site
Dallas, Texas, 75230
Withdrawn
Research Site
Dallas, Texas, 75234
Recruiting
Research Site
Dallas, Texas, 75246
Recruiting
Research Site
Decatur, Georgia, 30030
Recruiting
Research Site
Denver, Colorado, 80220
Withdrawn
Research Site
Detroit, Michigan, 48202
Recruiting
Research Site
East Point, Georgia, 30344
Recruiting
Research Site
East Providence, Rhode Island, 02914
Recruiting
Research Site
East Providence, Rhode Island, 02915
Recruiting
Research Site
Eatontown, New Jersey, 07724
Recruiting
Research Site
Edgewater, Florida, 32132
Recruiting
Research Site
Evansville, Indiana, 47714
Withdrawn
Research Site
Exton, Pennsylvania, 19341
Recruiting
Research Site
Fairhope, Alabama, 36532
Recruiting
Research Site
Fort Lauderdale, Florida, 33316
Recruiting
Research Site
Fremont, California, 94538
Recruiting
Research Site
Fullerton, California, 92835
Recruiting
Research Site
Garden City, Michigan, 48135
Recruiting
Research Site
Greenville, North Carolina, 27834
Recruiting
Research Site
Greenville, North Carolina, 27834
Suspended
Research Site
Hickory, North Carolina, 28601
Suspended
Research Site
Hollywood, Florida, 33021
Recruiting
Research Site
Honolulu, Hawaii, 96814
Completed
Research Site
Houston, Texas, 77004
Recruiting
Research Site
Houston, Texas, 77099
Recruiting
Research Site
Humble, Texas, 77346
Recruiting
Research Site
Hutchinson, Kansas, 67502
Recruiting
Research Site
Idaho Falls, Idaho, 83402
Recruiting
Research Site
Indianapolis, Indiana, 46202
Recruiting
Research Site
Inglewood, California, 90301
Withdrawn
Research Site
Iowa City, Iowa, 52242
Recruiting
Research Site
Jacksonville, North Carolina, 28546
Recruiting
Research Site
Jacksonville Beach, Florida, 32250
Recruiting
Research Site
Kansas City, Kansas, 66112
Recruiting
Research Site
Kansas City, Missouri, 64112
Recruiting
Research Site
Kansas City, Missouri, 64151
Recruiting
Research Site
Kenner, Louisiana, 70065
Withdrawn
Research Site
Kinston, North Carolina, 28504
Recruiting
Research Site
Knoxville, Tennessee, 37912
Recruiting
Research Site
Knoxville, Tennessee, 37938
Suspended
Research Site
Lake City, Florida, 32055
Recruiting
Research Site
Lakeland, Florida, 33805
Recruiting
Research Site
Langhorne, Pennsylvania, 19047
Recruiting
Research Site
Las Vegas, Nevada, 89109
Withdrawn
Research Site
Lawrenceville, Georgia, 30046
Recruiting
Research Site
Lewisville, Texas, 75057
Completed
Research Site
Los Alamitos, California, 90720
Recruiting
Research Site
Los Angeles, California, 90073
Recruiting
Research Site
Manassas, Virginia, 20110
Suspended
Research Site
Maywood, Illinois, 60153
Recruiting
Research Site
Media, Pennsylvania, 19063
Recruiting
Research Site
Melbourne, Florida, 32901
Recruiting
Research Site
Metairie, Louisiana, 70006
Recruiting
Research Site
Miami Lakes, Florida, 33014
Suspended
Research Site
Morehead City, North Carolina, 28557
Recruiting
Research Site
Nashville, Tennessee, 37232
Recruiting
Research Site
New Bedford, Massachusetts, 02740
Recruiting
Research Site
New Bern, North Carolina, 28562
Recruiting
Research Site
New Britain, Connecticut, 06051
Recruiting
Research Site
New York, New York, 10016
Recruiting
Research Site
Newport News, Virginia, 23606
Recruiting
Research Site
Norfolk, Nebraska, 68701
Recruiting
Research Site
Ocoee, Florida, 34761
Recruiting
Research Site
Orangeburg, South Carolina, 29118
Recruiting
Research Site
Pasadena, Texas, 77504
Recruiting
Research Site
Pearland, Texas, 77584
Suspended
Research Site
Port Charlotte, Florida, 33952
Recruiting
Research Site
Port Charlotte, Florida, 33952
Completed
Research Site
Port Orange, Florida, 32127
Recruiting
Research Site
Providence, Rhode Island, 02904
Completed
Research Site
Raleigh, North Carolina, 27609
Recruiting
Research Site
Richmond, Virginia, 23249
Recruiting
Research Site
Riverdale, Georgia, 30274
Suspended
Research Site
Riverview, Florida, 33578
Recruiting
Research Site
Rockford, Illinois, 61107
Recruiting
Research Site
Rocky Mount, North Carolina, 27804
Recruiting
Research Site
Saint Joseph, Michigan, 49085
Recruiting
Research Site
San Antonio, Texas, 78212
Recruiting
Research Site
San Diego, California, 92120
Withdrawn
Research Site
San Francisco, California, 94110
Withdrawn
Research Site
Sanford, North Carolina, 27330
Recruiting
Research Site
Seattle, Washington, 98195
Recruiting
Research Site
South Salt Lake, Utah, 84115
Recruiting
Research Site
Springfield, Oregon, 97477
Recruiting
Research Site
St Louis, Missouri, 63136
Recruiting
Research Site
Stanford, California, 94305
Recruiting
Research Site
Statesville, North Carolina, 28625
Recruiting
Research Site
Sun City, Arizona, 85351
Recruiting
Research Site
Tarzana, California, 91356
Recruiting
Research Site
Tucson, Arizona, 85741
Recruiting
Research Site
Washington D.C., District of Columbia, 20037
Recruiting
Research Site
West Des Moines, Iowa, 50266
Recruiting
Research Site
West Monroe, Louisiana, 71291
Recruiting
Research Site
Wichita, Kansas, 67214
Recruiting
Research Site
Wilmington, North Carolina, 28401
Recruiting
Research Site
Wilmington, North Carolina, 28412
Recruiting
Research Site
Winston-Salem, North Carolina, 27103
Recruiting
Research Site
Woodbridge, Virginia, 22192
Recruiting
Research Site
Worcester, Massachusetts, 01608
Recruiting

Other trials in United States

Japan63 sites, 60 recruiting

Research Site
Aira, 899-5421
Recruiting
Research Site
Amagasaki-shi, 660-8550
Recruiting
Research Site
Beppu-shi, 874-0011
Recruiting
Research Site
Chigasaki-shi, 253-0044
Recruiting
Research Site
Fujinomiya-shi, 418-0076
Withdrawn
Research Site
Hakodate-shi, 041-8680
Recruiting
Research Site
Hamamatsu, 432-8580
Recruiting
Research Site
Higashihiroshima-shi, 739-0041
Recruiting
Research Site
Iizuka-shi, 820-8505
Recruiting
Research Site
Inashiki-gun, 300-0395
Recruiting
Research Site
Iwata-shi, 438-8550
Recruiting
Research Site
Kagoshima, 890-0073
Recruiting
Research Site
Kamakura-shi, 247-0056
Recruiting
Research Site
Kanazawa, 920-8530
Recruiting
Research Site
Kashiwara-shi, 582-0005
Recruiting
Research Site
Kasugai-shi, 486-8510
Recruiting
Research Site
Kita-ku, 144-0001
Recruiting
Research Site
Kitakyushu, 802-8555
Recruiting
Research Site
Kitakyushu-shi, 807-0857
Recruiting
Research Site
Kobe, 650-0017
Recruiting
Research Site
Kobe, 650-0047
Withdrawn
Research Site
Kumagaya-shi, 360-0197
Recruiting
Research Site
Kurashiki Shi, 701 0192
Recruiting
Research Site
Kuse-gun, 613-0034
Recruiting
Research Site
Kuwana-shi, 511-0061
Recruiting
Research Site
Kyoto, 604-8845
Recruiting
Research Site
Kyoto, 612-8555
Recruiting
Research Site
Matsusaka-shi, 515-8557
Recruiting
Research Site
Matsuyama, 790-0024
Recruiting
Research Site
Matsuyama, 790-8524
Recruiting
Research Site
Meguro-ku, 153-0051
Recruiting
Research Site
Minatoku, 105-8471
Recruiting
Research Site
Minatoku, 108-0073
Recruiting
Research Site
Minokamo Shi, 505-8510
Recruiting
Research Site
Miyakonojo-shi, 885-0035
Recruiting
Research Site
Morioka, 020-0066
Recruiting
Research Site
Nagaoka-shi, 940-8621
Recruiting
Research Site
Naka, 311-0113
Recruiting
Research Site
Narita-shi, 286-8520
Recruiting
Research Site
Obihiro-shi, 080-0848
Recruiting
Research Site
Ōita, 870-0039
Recruiting
Research Site
Ōme, 198-0042
Recruiting
Research Site
Ōmihachiman, 523-0082
Recruiting
Research Site
Osaka, 534-0021
Withdrawn
Research Site
Osaka, 543-0035
Recruiting
Research Site
Osaka, 553-0003
Recruiting
Research Site
Osaka, 558-8558
Recruiting
Research Site
Osaka, 559-0012
Recruiting
Research Site
Saga, 849-8501
Recruiting
Research Site
Sapporo, 003-0026
Recruiting
Research Site
Sapporo, 060-0061
Recruiting
Research Site
Sapporo, 062-0921
Recruiting
Research Site
Sendai, 980-8574
Recruiting
Research Site
Sendai, 981-3281
Recruiting
Research Site
Shibuya-ku, 151-8528
Recruiting
Research Site
tabashi City, 173-0015
Recruiting
Research Site
Tanabe-shi, 646-8558
Recruiting
Research Site
Toyoake-shi, 470-1192
Recruiting
Research Site
Toyohashi, 441-8570
Recruiting
Research Site
Tsu, 514-8507
Recruiting
Research Site
Yaizu-shi, 425-8505
Recruiting
Research Site
Yokohama, 236-0004
Recruiting
Research Site
Yoshida-gun, 910-1193
Recruiting

Other trials in Japan

China62 sites, 60 recruiting

Research Site
Baotou, 014010
Recruiting
Research Site
Beijing, 100034
Recruiting
Research Site
Beijing, 100068
Withdrawn
Research Site
Beijing, CN-100083
Recruiting
Research Site
Changchun, 130041
Recruiting
Research Site
Changsha, 410008
Recruiting
Research Site
Changsha, 410015
Recruiting
Research Site
Changzhou, 272100
Recruiting
Research Site
Chengdu, 610000
Recruiting
Research Site
Chengdu, 610072
Recruiting
Research Site
Chongqing, 400010
Recruiting
Research Site
Dongwan, 523058
Recruiting
Research Site
Fuyang, 236012
Not yet recruiting
Research Site
Guangzhou, 510280
Recruiting
Research Site
Guangzhou, 510665
Recruiting
Research Site
Guangzhou, 510800
Recruiting
Research Site
Guangzhou, 511486
Recruiting
Research Site
Haikou, 570311
Recruiting
Research Site
Hefei, 230061
Recruiting
Research Site
Hefei, 230601
Recruiting
Research Site
Hengyang, 421001
Recruiting
Research Site
Heze, 274099
Recruiting
Research Site
Huaian, 223399
Recruiting
Research Site
Jiaxing, 314001
Recruiting
Research Site
Jilin City, 132011
Recruiting
Research Site
Jinan, 250021
Recruiting
Research Site
Jinhua, 321000
Recruiting
Research Site
Jining, 272006
Recruiting
Research Site
Lanzhou, 730000
Recruiting
Research Site
Linhai, 317000
Recruiting
Research Site
Linyi, 276003
Recruiting
Research Site
Luoyang, 471003
Recruiting
Research Site
Nanchang, 330006
Recruiting
Research Site
Nanning
Recruiting
Research Site
Ningbo, 315010
Recruiting
Research Site
Ningbo, 315099
Recruiting
Research Site
Ningbo, 315800
Recruiting
Research Site
Panjin, 124009
Recruiting
Research Site
Pingxiang, 337055
Recruiting
Research Site
Shanghai, 200061
Recruiting
Research Site
Shanghai, 200080
Recruiting
Research Site
Shanghai, 201199
Recruiting
Research Site
Shantou, 515041
Recruiting
Research Site
Shenyang, 110004
Recruiting
Research Site
Shenzhen, 518036
Recruiting
Research Site
Shenzhen, 518053
Recruiting
Research Site
Suzhou, 215004
Recruiting
Research Site
Taian, 271099
Recruiting
Research Site
Tianjin, 300192
Not yet recruiting
Research Site
Tianjin, CN-300052
Recruiting
Research Site
Wanzhou, 404000
Recruiting
Research Site
Wuhan, 430000
Recruiting
Research Site
Wuhan, 430010
Recruiting
Research Site
Wuxi, 214023
Recruiting
Research Site
Xi'an, 710061
Recruiting
Research Site
Xianyang, 750004
Withdrawn
Research Site
Yantai, 264000
Recruiting
Research Site
Yinchuan, 750004
Recruiting
Research Site
Zhengzhou, 450000
Recruiting
Research Site
Zhongshan, 528401
Recruiting
Research Site
Zhuzhou, 412007
Recruiting
Research Site
Zigong, 643000
Recruiting

Other trials in China

Poland36 sites, 32 recruiting

Research Site
Bialystok, 15-540
Recruiting
Research Site
Gdynia, 81-157
Recruiting
Research Site
Gdynia, 81-519
Recruiting
Research Site
Gmina Świecie, 86-100
Recruiting
Research Site
Jasło, 38-200
Active, not recruiting
Research Site
Katowice, 40-600
Recruiting
Research Site
Katowice, 40-648
Recruiting
Research Site
Katowice, 40-772
Recruiting
Research Site
Krakow, 30-688
Recruiting
Research Site
Krakow, 31-261
Recruiting
Research Site
Krakow, 31-501
Recruiting
Research Site
Krakow, 31-513
Recruiting
Research Site
Lodz, 91-363
Recruiting
Research Site
Lodz, 92-213
Recruiting
Research Site
Lublin, 20-718
Recruiting
Research Site
Piaseczno, 05-500
Withdrawn
Research Site
Poznan, 60-309
Recruiting
Research Site
Poznan, 60-354
Recruiting
Research Site
Poznan, 61-848
Recruiting
Research Site
Pruszków, 05-800
Recruiting
Research Site
Radom, 26-600
Recruiting
Research Site
Rzeszów, 35-055
Recruiting
Research Site
Szczecin, 70-111
Recruiting
Research Site
Szczecin, 71-434
Recruiting
Research Site
Szczecin, 71-526
Recruiting
Research Site
Tczew, 83-110
Recruiting
Research Site
Warsaw, 00-124
Recruiting
Research Site
Warsaw, 00-719
Recruiting
Research Site
Warsaw, 02-097
Recruiting
Research Site
Warsaw, 02-507
Recruiting
Research Site
Warsaw, 02-595
Active, not recruiting
Research Site
Warsaw, 02-798
Active, not recruiting
Research Site
Warsaw, 03-291
Recruiting
Research Site
Wroclaw, 50-304
Recruiting
Research Site
Wroclaw, 53-673
Recruiting
Research Site
Żywiec, 34-300
Recruiting

Other trials in Poland

Germany35 sites, 26 recruiting

Research Site
Bad Homburg, 61348
Recruiting
Research Site
Bamberg, 96049
Recruiting
Research Site
Berlin, 10117
Recruiting
Research Site
Berlin, 10629
Recruiting
Research Site
Berlin, 13509
Recruiting
Research Site
Bochum, 44787
Recruiting
Research Site
Brandenburg an der Havel, 14770
Recruiting
Research Site
Brandenburg an der Havel, 14776
Recruiting
Research Site
Dresden, 01279
Recruiting
Research Site
Essen, 45122
Recruiting
Research Site
Friedrichsthal, 66299
Withdrawn
Research Site
Görlitz, 02828
Recruiting
Research Site
Göttingen, 37075
Recruiting
Research Site
Hamburg, 21109
Withdrawn
Research Site
Hanover, 30449
Recruiting
Research Site
Hanover, 30459
Recruiting
Research Site
Hanover, 30625
Recruiting
Research Site
Heidelberg, 69115
Withdrawn
Research Site
Heidelberg, 69120
Recruiting
Research Site
Herne, 44625
Recruiting
Research Site
Karlsburg, 17495
Withdrawn
Research Site
Karlsruhe, 76133
Recruiting
Research Site
Karlsruhe, 76137
Withdrawn
Research Site
Landshut, 84034
Recruiting
Research Site
Mainz, 55131
Recruiting
Research Site
Obertshausen, 63179
Recruiting
Research Site
Offenbach, 63065
Recruiting
Research Site
Potsdam, 14473
Withdrawn
Research Site
Reinfeld (Holstein), 23858
Active, not recruiting
Research Site
Rostock, 18057
Withdrawn
Research Site
Rotenburg (Wümme), 27356
Recruiting
Research Site
Stuttgart, 70376
Withdrawn
Research Site
Ulm, 89081
Recruiting
Research Site
Wermsdorf, 04779
Recruiting
Research Site
Zwenkau, 04442
Recruiting

Other trials in Germany

France25 sites, 25 recruiting

Research Site
Amiens, 80054
Recruiting
Research Site
Bordeaux, 33076
Recruiting
Research Site
Boulogne-Billancourt, 92104
Recruiting
Research Site
Brest, 29200
Recruiting
Research Site
Clermont-Ferrand, 63003
Recruiting
Research Site
Créteil, 94000
Recruiting
Research Site
La Roche-sur-Yon, 85925
Recruiting
Research Site
Le Mans, 72037
Recruiting
Research Site
Limoges, 87042
Recruiting
Research Site
Lyon, 69437
Recruiting
Research Site
Marseille, 13005
Recruiting
Research Site
Nantes, 44093
Recruiting
Research Site
Nice, 06000
Recruiting
Research Site
Nîmes, 30000
Recruiting
Research Site
Paris, 75015
Recruiting
Research Site
Paris, 75018
Recruiting
Research Site
Pierre-Bénite, 69495
Recruiting
Research Site
Poitiers, 86021
Recruiting
Research Site
Quimper, 29000
Recruiting
Research Site
Reims, 51100
Recruiting
Research Site
Rouen, 76031
Recruiting
Research Site
Saint-Priest-en-Jarez, 42270
Recruiting
Research Site
Strasbourg, 67098
Recruiting
Research Site
Tours, 37044
Recruiting
Research Site
Vandœuvre-lès-Nancy, 54511
Recruiting

Other trials in France

Argentina22 sites, 18 recruiting

Research Site
Buenos Aires, C1060AAB
Recruiting
Research Site
CABA, C1426
Withdrawn
Research Site
CABA, C1426
Recruiting
Research Site
Ciudad Autonoma de Bs As, C1023AAB
Recruiting
Research Site
Ciudad de Buenos Aires, C1425AGC
Recruiting
Research Site
Córdoba, 5000
Withdrawn
Research Site
Córdoba, 5000
Active, not recruiting
Research Site
Córdoba, X5002HWE
Recruiting
Research Site
Córdoba, X5003DCE
Recruiting
Research Site
Córdoba, X5006CBI
Recruiting
Research Site
Córdoba, X5016LIG
Recruiting
Research Site
La Plata, B1900AVG
Recruiting
Research Site
Lanus, 1824
Recruiting
Research Site
Lanús Este, B1824KAJ
Recruiting
Research Site
Mar del Plata, 7600
Recruiting
Research Site
Mar del Plata, B7600
Recruiting
Research Site
Rosario, 2000
Recruiting
Research Site
San Nicolás, B2900DMH
Recruiting
Research Site
Santa Fe, S3000FWO
Recruiting
Research Site
Santiago del Estero, 4200
Recruiting
Research Site
Temperley, 1834
Withdrawn
Research Site
Temperley, CP1834
Recruiting

Other trials in Argentina

Canada21 sites, 19 recruiting

Research Site
Edmonton, Alberta, T6G 2P4
Recruiting
Research Site
Etobicoke, Ontario, M9W 6V1
Recruiting
Research Site
Halifax, Nova Scotia, B3H 1V7
Recruiting
Research Site
Laval, Quebec, H7T 2P5
Recruiting
Research Site
London, Ontario, N6A 5A5
Recruiting
Research Site
Montreal, Quebec, H1T 2M4
Recruiting
Research Site
Montreal, Quebec, H2X 0A9
Recruiting
Research Site
Montreal, Quebec, H4J 1C5
Recruiting
Research Site
Montreal, Quebec, H4J 1E3
Recruiting
Research Site
Oshawa, Ontario, L1G 2B9
Withdrawn
Research Site
Québec, Quebec, G1R 2J6
Recruiting
Research Site
Saint John, New Brunswick, E2L 4L2
Recruiting
Research Site
Sarnia, Ontario, N7T 4X3
Recruiting
Research Site
Surrey, British Columbia, V3T 0H1
Recruiting
Research Site
Toronto, Ontario, M3M 0B2
Recruiting
Research Site
Toronto, Ontario, M4G 3E8
Recruiting
Research Site
Toronto, Ontario, M5G 2N2
Recruiting
Research Site
Toronto, Ontario, M9V 4B4
Recruiting
Research Site
Vancouver, British Columbia, V6Z 1Y6
Withdrawn
Research Site
Waterloo, Ontario, N2T 0C1
Recruiting
Research Site
Winnipeg, Manitoba, R2V 3M3
Recruiting

Other trials in Canada

Bulgaria20 sites, 16 recruiting

Research Site
Byala, 7100
Recruiting
Research Site
Dupnitsa, 2600
Recruiting
Research Site
Gabrovo, 5300
Recruiting
Research Site
Gotse Delchev, 2900
Recruiting
Research Site
Kozloduy, 3320
Terminated
Research Site
Lom, 3600
Terminated
Research Site
Pernik, 2300
Recruiting
Research Site
Plovdiv, 4004
Recruiting
Research Site
Rousse, 7013
Recruiting
Research Site
Sandanski, 2800
Recruiting
Research Site
Sevlievo, 5403
Recruiting
Research Site
Sliven, 8800
Active, not recruiting
Research Site
Sofia, 1000
Recruiting
Research Site
Sofia, 1431
Recruiting
Research Site
Sofia, 1680
Recruiting
Research Site
Sofia
Recruiting
Research Site
Varna, 9000
Recruiting
Research Site
Varna, 9010
Recruiting
Research Site
Veliko Tarnovo, 5000
Recruiting
Research Site
Yambol, 8600
Withdrawn

Other trials in Bulgaria

Ukraine19 sites, 17 recruiting

Research Site
Chernivtsі, 58002
Recruiting
Research Site
Ivano-Frankivsk, 76008
Recruiting
Research Site
Kyiv, 01601
Recruiting
Research Site
Kyiv, 02002
Recruiting
Research Site
Kyiv, 03037
Recruiting
Research Site
Kyiv, 03049
Recruiting
Research Site
Kyiv, 03057
Recruiting
Research Site
Kyiv, 04050
Recruiting
Research Site
Kyiv, 04210
Recruiting
Research Site
Lviv, 79016
Recruiting
Research Site
Ternopil, 46000
Recruiting
Research Site
Ternopil, 46001
Recruiting
Research Site
Uzhhorod, 88014
Completed
Research Site
Uzhhorod, 88018
Recruiting
Research Site
Vinnytsia, 21001
Recruiting
Research Site
Vinnytsia, 21009
Recruiting
Research Site
Vinnytsia, 21018
Not yet recruiting
Research Site
Vinnytsia, 21029
Recruiting
Research Site
Zhytomyr, 10002
Terminated

Other trials in Ukraine

Brazil17 sites, 17 recruiting

Research Site
Barretos, 14784-400
Recruiting
Research Site
Belém, 66073-005
Recruiting
Research Site
Brasília, 70200-730
Recruiting
Research Site
Campina Grande do Sul, 83.430-000
Recruiting
Research Site
Campinas, 13060-080
Recruiting
Research Site
Campinas, 13060-803
Recruiting
Research Site
Curitiba, 80230-130
Recruiting
Research Site
Fortaleza, 60175-047
Recruiting
Research Site
Joinville, 89227-680
Recruiting
Research Site
Natal, 59020-500
Recruiting
Research Site
Porto Alegre, 90020-090
Recruiting
Research Site
Porto Alegre, 90160-093
Recruiting
Research Site
Rio de Janeiro, 20241-180
Recruiting
Research Site
São José do Rio Preto, 15090-000
Recruiting
Research Site
São Paulo, 04012-180
Recruiting
Research Site
São Paulo, 04038-031
Recruiting
Research Site
São Paulo, 05403-000
Recruiting

Other trials in Brazil

Italy16 sites, 16 recruiting

Research Site
Bassano del Grappa, 36031
Recruiting
Research Site
Bologna, 40138
Recruiting
Research Site
Desio, 20832
Recruiting
Research Site
Foggia, 71100
Recruiting
Research Site
Genoa, 16132
Recruiting
Research Site
Modena, 41124
Recruiting
Research Site
Naples, 80138
Recruiting
Research Site
Novara, 28100
Recruiting
Research Site
Padova, 35128
Recruiting
Research Site
Pavia, 27100
Recruiting
Research Site
Pisa, 56124
Recruiting
Research Site
Pordenone, 33170
Recruiting
Research Site
Roma, 00168
Recruiting
Research Site
Rozzano, 20089
Recruiting
Research Site
Torino, 10126
Recruiting
Research Site
Tradate, 21049
Recruiting

Other trials in Italy

Hungary15 sites, 11 recruiting

Research Site
Budapest, 1036
Recruiting
Research Site
Budapest, 1085
Recruiting
Research Site
Budapest, 1132
Recruiting
Research Site
Budapest, 1138
Recruiting
Research Site
Dunaújváros, 2400
Recruiting
Research Site
Encs, 3860
Withdrawn
Research Site
Győr, 9024
Recruiting
Research Site
Kaposvár, 7400
Recruiting
Research Site
Nyíregyháza, 4400
Recruiting
Research Site
Nyíregyháza, 4405
Withdrawn
Research Site
Szeged, 6724
Withdrawn
Research Site
Szeged, 6725
Recruiting
Research Site
Székesfehérvár, 8000
Recruiting
Research Site
Szolnok, 5004
Withdrawn
Research Site
Zalaegerszeg, 8900
Recruiting

Other trials in Hungary

South Africa15 sites, 11 recruiting

Research Site
Bellville, 7530
Recruiting
Research Site
Benoni, 1501
Recruiting
Research Site
Bloemfontein, 9301
Withdrawn
Research Site
Bloemfontein, 9301
Recruiting
Research Site
Cape Town, 7570
Recruiting
Research Site
Cape Town, 7925
Recruiting
Research Site
Durban, 4091
Recruiting
Research Site
Durban, 4092
Withdrawn
Research Site
Durban, 4450
Withdrawn
Research Site
Johannesburg, 1827
Recruiting
Research Site
KwaDukuza, 4449
Recruiting
Research Site
Lenasia, 1827
Recruiting
Research Site
Midrand, 1685
Recruiting
Research Site
Newton, 2113
Recruiting
Research Site
Parow, 7505
Withdrawn

Other trials in South Africa

Belgium14 sites, 13 recruiting

Research Site
Aalst, 9300
Recruiting
Research Site
Brussels, 1200
Recruiting
Research Site
Genk, 3600
Recruiting
Research Site
Hasselt, 3500
Recruiting
Research Site
Ieper, 8900
Recruiting
Research Site
Jette, 1090
Recruiting
Research Site
Kortrijk, 8500
Recruiting
Research Site
Leuven, 3000
Recruiting
Research Site
Liège, 4000
Recruiting
Research Site
Mechelen, 2800
Recruiting
Research Site
Namur, 5000
Recruiting
Research Site
Roeselare, 8800
Recruiting
Research Site
Ronse, 9600
Recruiting
Research Site
Sint-Truiden, 3800
Withdrawn

Other trials in Belgium

India14 sites, 12 recruiting

Research Site
Bangalore, 560060
Withdrawn
Research Site
Belagavi, 590010
Recruiting
Research Site
Hyderabad, 500 034
Withdrawn
Research Site
Hyderabad, 500082
Recruiting
Research Site
Kolkata, 700014
Recruiting
Research Site
Kolkata, 700020
Recruiting
Research Site
Madurai, 625107
Recruiting
Research Site
Mumbai, 400026
Recruiting
Research Site
New Delhi, 110001
Recruiting
Research Site
New Delhi, 110017
Recruiting
Research Site
New Delhi, 110029
Recruiting
Research Site
Pune, 411013
Recruiting
Research Site
Vijayawada, 520 008
Recruiting
Research Site
Vijayawada, 522002
Recruiting

Other trials in India

Peru13 sites, 10 recruiting

Research Site
Arequipa, AREQUIPA01
Suspended
Research Site
Bellavista, CALLAO 2
Recruiting
Research Site
Chorrillos, Lima 9
Recruiting
Research Site
Cusco, CUSCO 01
Not yet recruiting
Research Site
Lima, 14
Recruiting
Research Site
Lima, 15036
Recruiting
Research Site
Lima, 15046
Recruiting
Research Site
Lima, 15046
Withdrawn
Research Site
Lima, 15072
Not yet recruiting
Research Site
Lima, 15074
Withdrawn
Research Site
Lima, 15088
Recruiting
Research Site
Lima, LIMA 01
Recruiting
Research Site
Piura, 20001
Recruiting

Other trials in Peru

Czechia12 sites, 7 recruiting

Research Site
Brandýs nad Labem, 250 01
Withdrawn
Research Site
Frýdek-Místek, 738 01
Withdrawn
Research Site
Jilemnice, 514 01
Recruiting
Research Site
Krnov, 794 01
Completed
Research Site
Mladá Boleslav, 293 01
Recruiting
Research Site
Náchod, 547 01
Recruiting
Research Site
Olomouc, 772 00
Withdrawn
Research Site
Pilsen, 323 00
Recruiting
Research Site
Prague, 104 00
Recruiting
Research Site
Prague, 140 00
Recruiting
Research Site
Prague, 160 00
Suspended
Research Site
Slaný, 274 01
Recruiting

Other trials in Czechia

Israel12 sites, 11 recruiting

Research Site
Afula, 18101
Recruiting
Research Site
Ashdod, 7747629
Recruiting
Research Site
Be’er Ya‘aqov, 70300
Recruiting
Research Site
Haifa, 3109601
Recruiting
Research Site
Haifa, 34362
Recruiting
Research Site
Jerusalem, 91120
Withdrawn
Research Site
Kfar Saba, 44281
Recruiting
Research Site
Nahariya, 22100
Recruiting
Research Site
Petah Tikva, 49372
Recruiting
Research Site
Rehovot, 76100
Recruiting
Research Site
Tel Aviv, 6423906
Recruiting
Research Site
Tiberias, 15208
Recruiting

Other trials in Israel

Mexico12 sites, 12 recruiting

Research Site
Chihuahua City, 31000
Recruiting
Research Site
Cuauhtémoc, 06700
Recruiting
Research Site
D.F, 14000
Recruiting
Research Site
Durango, 34000
Recruiting
Research Site
Guadalajara, 44670
Recruiting
Research Site
Guadalajara, 44690
Recruiting
Research Site
Mazatlán, 82000
Recruiting
Research Site
Mazatlán, 82110
Recruiting
Research Site
Mérida, 97130
Recruiting
Research Site
San Luis Potosí City, 78250
Recruiting
Research Site
Veracruz, 91855
Recruiting
Research Site
Zapopan, 45138
Recruiting

Other trials in Mexico

South Korea12 sites, 12 recruiting

Research Site
Ansan-si, 15355
Recruiting
Research Site
Anyang-si, 14068
Recruiting
Research Site
Busan, 49241
Recruiting
Research Site
Cheonan-si, 31151
Recruiting
Research Site
Goyang-si, 10380
Recruiting
Research Site
Gwangju, 61469
Recruiting
Research Site
Seongnam-si, 13620
Recruiting
Research Site
Seoul, 03722
Recruiting
Research Site
Seoul, 04401
Recruiting
Research Site
Seoul, 07061
Recruiting
Research Site
Wŏnju, 26426
Recruiting
Research Site
Yangsan, 50612
Recruiting

Other trials in South Korea

Spain12 sites, 11 recruiting

Research Site
A Coruña, 15006
Recruiting
Research Site
Almería, 4009
Recruiting
Research Site
Badalona, 08916
Recruiting
Research Site
L'Hospitalet de Llobregat, 08907
Recruiting
Research Site
Majadahonda, 28222
Recruiting
Research Site
Málaga, 29010
Recruiting
Research Site
Palma deMallorca, 07010
Suspended
Research Site
Pamplona, 31008
Recruiting
Research Site
Seville, 41013
Recruiting
Research Site
Seville, 41071
Recruiting
Research Site
Valencia, 46010
Recruiting
Research Site
Valencia, 46017
Recruiting

Other trials in Spain

United Kingdom12 sites, 12 recruiting

Research Site
Bradford, BND9 6RJ
Recruiting
Research Site
Bristol, BS105NB
Recruiting
Research Site
Canterbury, CT1 3NG
Recruiting
Research Site
Cardiff, CF14 4XW
Recruiting
Research Site
Dundee, DD1 9SY
Recruiting
Research Site
Glasgow, G51 4TF
Recruiting
Research Site
Hounslow, TW3 3LN
Recruiting
Research Site
London, E1 1FR
Recruiting
Research Site
London, N16 6UH
Recruiting
Research Site
London, SE5 9RS
Recruiting
Research Site
Salford, M6 8HD
Recruiting
Research Site
Swansea, SN6 6NL
Recruiting

Other trials in United Kingdom

Philippines11 sites, 8 recruiting

Research Site
Cebu City, 6000
Recruiting
Research Site
Davao City, 8000
Recruiting
Research Site
Davao City, PH-8000
Recruiting
Research Site
Davao City, PH-8000
Not yet recruiting
Research Site
Iloilo City, 5000
Recruiting
Research Site
Laguna, 4024
Recruiting
Research Site
Manadaluyong City, 1552
Recruiting
Research Site
Manila, 1000
Withdrawn
Research Site
Quezon City, 1101
Recruiting
Research Site
Quezon City
Withdrawn
Research Site
San Fernando City, 2000
Withdrawn

Other trials in Philippines

Romania11 sites, 8 recruiting

Research Site
Brasov, 500073
Withdrawn
Research Site
Bucharest, 042122
Recruiting
Research Site
Bucharest, 060044
Recruiting
Research Site
Bucharest, 22325
Withdrawn
Research Site
Bucharest, 22328
Recruiting
Research Site
Cluj-Napoca, 400349
Recruiting
Research Site
Craiova, 200349
Recruiting
Research Site
Craiova, 200642
Recruiting
Research Site
Oradea, 410469
Recruiting
Research Site
Suceava, 720237
Terminated
Research Site
Timișoara, 300723
Recruiting

Other trials in Romania

Colombia10 sites, 10 recruiting

Research Site
Barranquilla, 080020
Recruiting
Research Site
Barranquilla, 080020
Not yet recruiting
Research Site
Barranquilla, 80007
Recruiting
Research Site
Bogotá, 111411
Recruiting
Research Site
Cali, 760042
Recruiting
Research Site
Manizales, 170004
Not yet recruiting
Research Site
Medellín, 050030
Recruiting
Research Site
Medellín, 050034
Recruiting
Research Site
Montería, 230002
Recruiting
Research Site
Pasto, 520002
Recruiting

Other trials in Colombia

Serbia10 sites, 6 recruiting

Research Site
Belgrade, 11000
Recruiting
Research Site
Belgrade, 11000
Withdrawn
Research Site
Belgrade, 11070
Recruiting
Research Site
Belgrade, 11120
Withdrawn
Research Site
Kamenitz, 21204
Recruiting
Research Site
Kragujevac, 34000
Recruiting
Research Site
Kragujevac, 34000
Withdrawn
Research Site
Niš, 18000
Recruiting
Research Site
Novi Sad, 21000
Withdrawn
Research Site
Novi Sad, 21000
Recruiting

Other trials in Serbia

Slovakia10 sites, 8 recruiting

Research Site
Košice, 040 01
Recruiting
Research Site
Kráľovský Chlmec, 077 01
Withdrawn
Research Site
Myjava, 90701
Recruiting
Research Site
Nitra, 949 11
Recruiting
Research Site
Prešov, 080 01
Recruiting
Research Site
Prešov, 080 01
Withdrawn
Research Site
Púchov, 020 01
Recruiting
Research Site
Trenčín, 91171
Recruiting
Research Site
Trnava, 917 02
Recruiting
Research Site
Žilina, 010 01
Recruiting

Other trials in Slovakia

Turkey (Türkiye)10 sites, 10 recruiting

Research Site
Adana, 01060
Recruiting
Research Site
Adapazarı, 54100
Recruiting
Research Site
Altındağ, 06230
Recruiting
Research Site
Ankara, 06530
Recruiting
Research Site
Antalya, 07100
Recruiting
Research Site
Haliliye, 63040
Recruiting
Research Site
Kahramanmaraş, 46040
Recruiting
Research Site
Kayseri, 38039
Recruiting
Research Site
Kocaeli, 41380
Recruiting
Research Site
Şahinbey, 27310
Recruiting

Other trials in Turkey (Türkiye)

Australia9 sites, 8 recruiting

Research Site
Adelaide, 5000
Recruiting
Research Site
Darlinghurst, 2010
Completed
Research Site
Elizabeth Vale, 5112
Recruiting
Research Site
Gosford, 2250
Recruiting
Research Site
North Tamworth, 2340
Recruiting
Research Site
Perth, 6000
Recruiting
Research Site
Southport, 4215
Recruiting
Research Site
St Leonards, 2065
Recruiting
Research Site
Wollongong, 2500
Recruiting

Other trials in Australia

Netherlands9 sites, 9 recruiting

Research Site
Amersfoort, 3813 TZ
Recruiting
Research Site
Amsterdam, 1105 AZ
Recruiting
Research Site
Dordrecht, 3318 AT
Recruiting
Research Site
Groningen, 9713 GZ
Recruiting
Research Site
Hilversum, 1212 VG
Recruiting
Research Site
Leiden, 2333 ZA
Recruiting
Research Site
Maastricht, 6229 HX
Recruiting
Research Site
Nieuwegein, 3435 CM
Recruiting
Research Site
Zwolle, 8025 AB
Recruiting

Other trials in Netherlands

Thailand9 sites, 5 recruiting

Research Site
Bangkok, 10330
Active, not recruiting
Research Site
Bangkok, 10400
Recruiting
Research Site
Bangkok, 10700
Recruiting
Research Site
Banphaeo, 74120
Recruiting
Research Site
Hat Yai, 90110
Active, not recruiting
Research Site
Khon Kaen, 40002
Active, not recruiting
Research Site
Mueang, 50200
Recruiting
Research Site
Phutthamonthon, 73170
Recruiting
Research Site
Ubonratchathani, 34000
Active, not recruiting

Other trials in Thailand

Greece8 sites, 8 recruiting

Research Site
Alexandroupoli, 68100
Recruiting
Research Site
Athens, 11527
Recruiting
Research Site
Heraklion, 71500
Recruiting
Research Site
Ioannina, 45500
Recruiting
Research Site
Pátrai, 26504
Recruiting
Research Site
Thessaloniki, 54636
Recruiting
Research Site
Thessaloniki, 54642
Recruiting
Research Site
Thessaloniki, 57010
Recruiting

Other trials in Greece

Malaysia8 sites, 8 recruiting

Research Site
Ampang, 68000
Recruiting
Research Site
Cheras, 56000
Recruiting
Research Site
Ipoh, 30990
Recruiting
Research Site
Kajang, 43000
Recruiting
Research Site
Kota Bharu, 15586
Recruiting
Research Site
Kuala Lumpur, 59100
Recruiting
Research Site
Seremban, 70300
Recruiting
Research Site
Seri Manjung, 32040
Recruiting

Other trials in Malaysia

Taiwan8 sites, 8 recruiting

Research Site
New Taipei City, 220
Recruiting
Research Site
Taichung, 402
Recruiting
Research Site
Taichung, 433004
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taipei, 110
Recruiting
Research Site
Taipei, TAIWAN
Recruiting
Research Site
Taoyuan, 333
Recruiting
Research Site
Yung Kang City, 71044
Recruiting

Other trials in Taiwan

Vietnam8 sites, 7 recruiting

Research Site
Can Tho, 920000
Recruiting
Research Site
Da Nang, 550000
Recruiting
Research Site
Haiphong, 180000
Recruiting
Research Site
Hanoi, 10000
Recruiting
Research Site
Ho Chi Minh City, 700000
Recruiting
Research Site
Ho Chi Minh City, 700000
Withdrawn
Research Site
Ho Chi Minh City, 70000
Recruiting
Research Site
Rach Gia, 920000
Recruiting

Other trials in Vietnam

Chile7 sites, 6 recruiting

Research Site
Araucania, 4781151
Recruiting
Research Site
Santiago, 7500922
Recruiting
Research Site
Santiago, 8331143
Recruiting
Research Site
Talcahuano, 4270918
Recruiting
Research Site
Valdivia, 5090000
Recruiting
Research Site
Victoria, 4720000
Recruiting
Research Site
Viña del Mar, 2540488
Withdrawn

Other trials in Chile

Denmark7 sites, 7 recruiting

Research Site
Aalborg, 9000
Recruiting
Research Site
Aarhus, 8200
Recruiting
Research Site
Copenhagen E, 2100
Recruiting
Research Site
Herlev, 2730
Recruiting
Research Site
Herning, 7400
Recruiting
Research Site
Holbæk, 4300
Recruiting
Research Site
Kolding, 6000
Recruiting

Other trials in Denmark

Saudi Arabia7 sites, 6 recruiting

Research Site
Al-Ahsa, 36428
Recruiting
Research Site
Dammam, 31444
Recruiting
Research Site
Riyadh, 11211
Withdrawn
Research Site
Riyadh, 11426
Recruiting
Research Site
Riyadh, 11462
Recruiting
Research Site
Riyadh, 12231
Not yet recruiting
Research Site
Riyadh/MENA, 11426
Recruiting

Other trials in Saudi Arabia

Sweden6 sites, 6 recruiting

Research Site
Huddinge, 141 57
Recruiting
Research Site
Karlstad, 651 85
Recruiting
Research Site
Linköping, 581 85
Recruiting
Research Site
Stockholm, 18288
Recruiting
Research Site
Uppsala, 751 85
Recruiting
Research Site
Vaxjo, 352 34
Recruiting

Other trials in Sweden

Egypt5 sites

Research Site
Cairo, 11566
Withdrawn
Research Site
Cairo, 11734
Withdrawn
Research Site
Cairo, 4540046
Withdrawn
Research Site
Dakahlia, 35516
Withdrawn
Research Site
Dakahlia, 7650030
Withdrawn

Other trials in Egypt

Singapore4 sites, 4 recruiting

Research Site
Singapore, 119074
Recruiting
Research Site
Singapore, 169608
Recruiting
Research Site
Singapore, 308433
Recruiting
Research Site
Singapore, 529889
Recruiting

Other trials in Singapore

About this study

Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure

Read the detailed description

The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, HF events, or CV death in participants with CKD and HTN.

This study consists of a 4-week dapagliflozin Run-in Period for participants untreated with SGLT2i at screening, and a double-blinded period where participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin.

Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomisation. Thereafter visits will occur approximately every 4 months.

The study closure procedures will be initiated when the predetermined number of primary endpoint events is predicted to have occurred (N = 845) ie, the PACD. All randomised participants including any participants who have prematurely discontinued study intervention will be scheduled for a SCV within 6 weeks of the PACD. This period can be extended by AstraZeneca.

In case of premature discontinuation of blinded study intervention, participants will continue in the study and receive dapagliflozin 10 mg, unless the participant meets dapagliflozin specific discontinuation criteria. Baxdrostat/placebo should not be administered without dapagliflozin: baxdrostat/placebo should be interrupted if dapagliflozin is interrupted (baxdrostat/placebo may be resumed with dapagliflozin, if dapagliflozin is resumed), and should be permanently discontinued if dapagliflozin is permanently discontinued. If study intervention is temporarily or permanently discontinued, the participant should remain in the study, and it is important that the scheduled study visits (including the PTDV for participants with permanent discontinuation of study intervention) and data collection continue according to the study protocol until the SCV.

Conditions: Chronic Kidney Disease and Hypertension
Being tested: Baxdrostat/dapagliflozin, Placebo/dapagliflozin
Keywords: Chronic kidney disease, Hypertension, Blood pressure, Baxdrostat, Dapagliflozin, Event-Driven, Outcome
Medical subject headings: Renal Insufficiency, Chronic, Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Baxdrostat/dapagliflozinDrug
Also called Baxdrostat CIN-107
baxdrostat tablet
dapagliflozin tablet
Placebo/dapagliflozinDrug
dapagliflozin tablet
placebo tablet

Study groups in NCT06742723
Study group	Role	What they receive
Baxdrostat/dapagliflozin	Experimental	Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a lower dose of baxdrostat and standard dose dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose. Receives: Drug: Baxdrostat/dapagliflozin
Placebo/dapagliflozin	Placebo comparator	Patients will receive one dose of dapagliflozin comparator in combination with matching placebo daily. Receives: Drug: Placebo/dapagliflozin

What is being measured

The primary outcome is the main question the study is designed to answer.

To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.
Time to the first occurrence of any of the components of the composite of:
Kidney disease progression
- ≥ 50% sustained decline in eGFR
- Onset of kidney failure:
- Sustained eGFR < 15 mL/min/1.73 m2 or
- Chronic dialysis treatment or
- Receiving a kidney transplant or
- Death with a renal primary cause (death due to kidney failure when dialysis is not given)
CV events
- HF with or without hospitalisation
- CV death
Measured: Up to 37 months

Secondary outcomes (4)

To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure or CV death.
Time to the first occurrence of any of the components of the composite of:
- ≥ 50% sustained decline in eGFR
- Onset of kidney failure:
- Sustained eGFR < 15 mL/min/1.73 m2 or
- Chronic dialysis treatment or
- Receiving a kidney transplant or
- Death with a renal primary cause (death due to kidney failure when dialysis is not given)
- CV death
Measured: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of MACE (Major Adverse Cardiac Events).
Time to the first occurrence of any of the components of the composite of: CV (cardiovascular) death, HF (heart failure) with and without hospitalization, Myocardial Infraction, Stroke
Measured: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of CV (cardiovascular) death.
Time to the first occurrence of any of the components of the composite of CV (cardiovascular) death
Measured: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of all-cause death.
Time to the first occurrence of any of the components of the composite of all-cause death
Measured: Up to 37 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

3 Mar 202518 Dec 2029

First posted19 Dec 2024
Study start3 Mar 2025
Primary completion18 Dec 2029 (estimated)
Study completion18 Dec 2029 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Chronic Kidney Disease and HypertensionStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: International, multi-centre, randomised, double-blind, parallel-group, placebo-controlled, event-driven, outcome
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 5,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06742723
Sponsor's protocol ID: D6972C00002
Other IDs: 2023-506460-14-00, 2023
Acronym: BaxDuo-Pacific
Status last verified: Nov 2026
First submitted: 16 Dec 2024
Last updated: 6 Nov 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Publications

Yeung EK, Rangaswami J, Tuttle KR, Grams ME, Tangri N, Vaduganathan M, Neuen BL. A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Clin J Am Soc Nephrol. 2026 Jun 23. doi: 10.2215/CJN.0000001158. Online ahead of print.
PubMed 42335037
Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026 Feb 1;37(2):299-311. doi: 10.1681/ASN.0000000849. Epub 2025 Sep 6.
PubMed 40913594

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Not yet recruiting
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
Hypertension (HTN), CKD - Chronic Kidney Disease
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Atherosclerosis, Cardiovascular Disease

All Chronic Kidney Disease and Hypertension trials

Study at a glance

From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
ClinicalTrials.gov ID: NCT06742723
Acronym / sponsor ID: BaxDuo-Pacific / D6972C00002
Conditions: Chronic Kidney Disease and Hypertension
Keywords: Chronic kidney disease, Hypertension, Blood pressure, Baxdrostat, Dapagliflozin, Event-Driven, Outcome
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 5,000 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 3 Mar 2025 (actual)
Primary completion: 18 Dec 2029 (estimated)
Study completion: 18 Dec 2029 (estimated)
First posted: 19 Dec 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomisation. Thereafter visits will occur approximately every 4 months.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: International, multi-centre, randomised, double-blind, parallel-group, placebo-controlled, event-driven, outcome

Arm	Type	Receives
Baxdrostat/dapagliflozin	Experimental	Drug: Baxdrostat/dapagliflozinParticipants randomised to the baxdrostat/dapagliflozin arm will initially receive a lower dose of baxdrostat and standard dose dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.
Placebo/dapagliflozin	Placebo comparator	Drug: Placebo/dapagliflozinPatients will receive one dose of dapagliflozin comparator in combination with matching placebo daily.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (15 listed)

Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent.
Participants with (a) or (b):
[obsolete]
Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit.
Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit.

Key exclusion criteria (14 listed)

Systolic blood pressure > 180 mmHg, or diastolic BP > 110 mmHg at screening.
Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening.
Serum sodium < 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit).
For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion.
For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Baxdrostat/dapagliflozinAlso: Baxdrostat CIN-107baxdrostat tablet dapagliflozin tablet	Drug	Baxdrostat/dapagliflozin
Placebo/dapagliflozindapagliflozin tablet placebo tablet	Drug	Placebo/dapagliflozin

Primary outcome

To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.
Time frame: Up to 37 months
Time to the first occurrence of any of the components of the composite of: Kidney disease progression * ≥ 50% sustained decline in eGFR * Onset of kidney failure: * Sustained eGFR < 15 mL/min/1.73 m2 or * Chronic dialysis treatment or * Receiving a kidney transplant or * Death with a renal primary cause (death due to kidney failure when dialysis is not given) CV events * HF with or without hospitalisation * CV death

4 secondary outcomes

To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure or CV death.
Time frame: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of MACE (Major Adverse Cardiac Events).
Time frame: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of CV (cardiovascular) death.
Time frame: Up to 37 months
To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of all-cause death.
Time frame: Up to 37 months

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Derived from this study: PubMed 42335037Yeung EK, Rangaswami J, Tuttle KR, Grams ME, Tangri N, Vaduganathan M, Neuen BL. A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Clin J Am Soc Nephrol. 2026 Jun 23. doi: 10.2215/CJN.0000001158. Online ahead of print.
Derived from this study: PubMed 40913594Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026 Feb 1;37(2):299-311. doi: 10.1681/ASN.0000000849. Epub 2025 Sep 6.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Related trials for Chronic Kidney Disease and Hypertension

Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Not yet recruiting
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
Hypertension (HTN), CKD - Chronic Kidney Disease
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Atherosclerosis, Cardiovascular Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

771 sites in 42 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Baxdrostat/dapagliflozin in people with Chronic Kidney Disease and Hypertension, run by AstraZeneca at 771 sites in 42 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 771 sites in United States, Japan, China, Poland, Germany and 37 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death. (time frame: Up to 37 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06742723, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.